Peptinovo Biopharma’s Targeted Cancer Drug Platform Approved for Clinical Trials

Peptinovo Biopharma Logo

Peptinovo Biopharma, an Ann Arbor–based biotechnology company pioneering targeted cancer therapies through its first-of-its-kind proprietary PALM™ nanotechnology, today announced it has received approval to initiate its first human clinical trials in Australia. The milestone clears the way for the company to begin enrolling cancer patients in the coming months.